Melanotan II
Men's HealthMen's-health clinics treat Melanotan II as one component in a layered hormonal optimisation framework. The cyclic α-MSH analogue with MC4R activity — tanning effects plus the sexual-response effects that led to its derivative bremelanotide (PT-141). The relevant questions for male users are: does it interact with the HPG axis, is it compatible with current TRT or HCG protocols, and what are its effects on prostate, hematocrit, and cardiovascular indices over a ~30 min-pharmacokinetics Melanotan II cycle? The sections below address each.
Key Takeaways
Male-physiology lens: Melanotan II is evaluated against HPG-axis interaction, TRT compatibility, and prostate / cardiovascular considerations. Mechanism: Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5). Male monitoring: baseline testosterone (total/free), LH, FSH, estradiol, prolactin, SHBG; 6-8 week follow-up panel. Male dose: 0.25-0.5 mg daily during loading, then 1-2x weekly via subq/intranasal; cycle 8-12 weeks. Male-physiology stack partners: Kisspeptin, Gonadorelin (GnRH), PT-141.
Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5). MC1R drives pigmentation; MC4R drives appetite suppression and sexual response; MC3R/5R contribute to energy expenditure and sebaceous secretion. Cyclic structure resists enzymatic degradation. For men, the downstream consequences of this mechanism are evaluated against four operational domains: HPG-axis interaction, recovery and body composition, sexual function and prostate, and integration with concurrent TRT or HCG protocols. Melanotan II's relationship to each is examined below.
Compatibility with TRT and post-cycle protocols
For men currently on TRT or planning a post-cycle restart, Melanotan II is typically compatible because it does not directly engage the HPG axis. The dominant interaction to watch for is on the metabolic and recovery layers rather than the hormonal layer. Where the molecule's pharmacology overlaps with HCG, gonadorelin, or kisspeptin, dose layering is the standard approach.
Sexual function and prostate considerations
Where Melanotan II alters circulating LH, testosterone, or local androgen signalling, prostate considerations become relevant for men over 40. Baseline PSA, periodic re-check, and avoidance of stacking that compounds androgenic load are all reasonable precautions. For molecules whose effects are predominantly outside the HPG axis, the prostate consideration is largely background.
Interaction with the HPG axis
Melanotan II's relationship to the male HPG axis is one of the central practical questions. Direct receptor-level engagement of the HPG axis is not the principal mechanism, but downstream effects on testosterone, LH/FSH, and prolactin can still occur and warrant baseline and follow-up labs in male users. The practical takeaway is that any male user beginning a course of Melanotan II should have a baseline hormone panel and a follow-up at 6–8 weeks to detect drift.
For hpg axis support in male users, Melanotan II is most-effective when paired with comprehensive labs (testosterone total/free, LH, FSH, estradiol sensitive, prolactin, SHBG) at baseline and follow-up. Cycle length 8–12 weeks with re-evaluation.
Where male users target erectile function, Melanotan II is typically integrated with the broader hormonal protocol — TRT, kisspeptin, gonadorelin, or HCG — rather than used in isolation. The integration approach varies by clinic.
Muscle Mass in men responds to Melanotan II with effect sizes that vary substantially by baseline status — men with documented suboptimal status respond more strongly than those at the upper end of normal. The protocol pattern in clinical use reflects this.
For recovery in male users, Melanotan II is most-effective when paired with comprehensive labs (testosterone total/free, LH, FSH, estradiol sensitive, prolactin, SHBG) at baseline and follow-up. Cycle length 8–12 weeks with re-evaluation.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 0.25-0.5 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 1.25-0.5 mg | 4–6 weeks initial cycle |
| Men's Health focus | SubQ | 0.25-0.5 mg | Daily during loading, then 1-2x weekly |
| Maintenance phase | SubQ | 1.25-0.5 mg | Ongoing with periodic pauses |
Dose timing for Melanotan II is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Melanotan II stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from men's-health clinicians.
- Melanotan II + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with Melanotan II's mechanism in male physiology protocols.
- Melanotan II + Gonadorelin (GnRH): Binds the GnRH receptor on anterior pituitary gonadotrophs in a pulsatile fashion to stimulate LH (and to a lesser extent FSH) release. Pairs naturally with Melanotan II's mechanism in male physiology protocols.
- Melanotan II + PT-141: Activates MC4R in the hypothalamus and other CNS regions involved in sexual response. Pairs naturally with Melanotan II's mechanism in male physiology protocols.
- Melanotan II + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Melanotan II's mechanism in male physiology protocols.
Nausea (especially early), spontaneous erections in men, marked appetite suppression, hyperpigmentation. Watch new moles closely. Avoid in melanoma history.
Lens-specific safety considerations for male physiology use of Melanotan II: Nausea (especially early), spontaneous erections in men, marked appetite suppression, hyperpigmentation. Watch new moles closely. Avoid in melanoma history. Additional male physiology monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Melanotan II | Cyclic α-MSH analogue | ~30 min | Men's Health |
| Kisspeptin | Hypothalamic upstream regulator of GnRH | ~28 min IV | The upstream master regulator of GnRH neurons — driving the entire HPG axis from above |
| Gonadorelin (GnRH) | Hypothalamic decapeptide | ~2-4 min | The natural decapeptide that drives pituitary release of LH and FSH — used clinically and increasingly as an HCG alternative during testosterone therapy |
| PT-141 | Melanocortin receptor agonist | ~2-3 hr | An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women |
How does Melanotan II affect the HPG axis?
Is Melanotan II compatible with TRT?
Will Melanotan II affect fertility or sperm quality?
Can I use Melanotan II during a cut?
What is the standard dosing protocol for Melanotan II?
What is the mechanism of action of Melanotan II?
Start a Melanotan II Protocol
Alukard provides physician-supervised men's health protocols with GMP-certified Melanotan II and GMP-certified compounds with comprehensive hormone panels.
Get ProtocolQuick Facts
- Molecular weight
- 1024 Da
- Sequence length
- 7 aa
- Half-life
- ~30 min
- WADA
- Not on prohibited list
- FDA
- Unapproved
- Research
- Mechanistic + off-label
All male physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Melanotan II unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Male Physiology Protocol for Melanotan II
Alukard provides physician-supervised men's health protocols with GMP-certified compounds with comprehensive hormone panels.
HIPAA Compliant · GMP Certified · Physician Supervised